JB Pharma Q4 Results: Net profit rises 4% to Rs 88 crore

JB Pharma on Wednesday said its net profit rose 4% year-on-year (YoY) to Rs 88 crore for the fourth quarter ended March 31, 2023.

The PE firm KKR-backed company had reported net Rs 85 crore in the January-March quarter of 2021-22 fiscal.

The net profit was impacted for the quarter primarily due to Rs 14 crore rise in finance cost on term loan for brand acquisitions.


Revenue grew 22% YoY to Rs 762 crores in Q4FY23. Operating earnings before interest, depreciation and tax increased by 21% to Rs 181 crores.

Operating cash flow improved in FY23 to Rs 626 crores as compared to Rs 170 crores in FY22, strongly aided by the higher proportion of India business and a strong focus on working capital management, which includes inventory and receivables.

Domestic business revenue grew 29% YoY to Rs 380 crores in Q4FY23.JB Pharma grew 30% for Q4 FY23, double the industry growth rate of 15%.

As per IQVIA Mar 2023 data, all 6 top brands of JB Pharma gained ranks.

International business grew by 16% to Rs 382 crores in Q4FY23 led by demand revival in Russia, South Africa private business and strong momentum of contract manufacturing business